This study explores the effects of two drugs, acalabrutinib and obinutuzumab, on patients with certain types of untreated lymphoma. Lymphoma is a type of blood cancer that affects the lymphatic system. Acalabrutinib works by blocking the growth of cancer cells, while obinutuzumab is an immunotherapy that uses the body's immune system to fight cancer. The goal is to see if these drugs can effectively treat the cancer and improve the patients' quality of life.

Key points:

• The study will last up to 12 cycles, with each cycle lasting 28 days.
• Participants will receive acalabrutinib orally twice daily, and obinutuzumab through an IV on specific days during the cycles.
• After the treatment, participants will be monitored for disease progression every few months.

Participants must be adults who have not received prior treatment for their lymphoma. They will need to agree to use contraception during the study and for a period after. People with certain health conditions, like active infections or prior cancer treatments, may not be eligible. This study aims to assess the effectiveness, safety, and impact on life quality of these treatments.